Replies to post #209676 on Biotech Values

[DewDiligence]

I thought the full enrollment of RVNC's [phase-3] trials was the pricing trigger [today].

True. Although the swift completion of phase-3 enrollment should not have been a surprise to anyone who's been following RNVC closely, it apparently was a surprise to some investors.

CEO, Dan Browne has been saying for months that these phase-3 trials would enroll very quickly. Why wouldn't they? There's a huge pool of people to draw on who have glabellar lines and would gladly opt for a 2/3 chance of receiving free treatment with botulinum toxin.